ERK5 inhibition induces autophagic flux
ERK5 inhibition induces autophagic flux

Image source: UAB

News • Impaired proliferation and induced cell death

Newfound mechanism could stop cancer cells in their tracks

Researchers at the Universitat Autònoma de Barcelona and Vall d’Hebron identified the mechanism by which inhibitors of the ERK5 protein kinase impair the proliferation of cancer cells and induce their death.

The results, obtained using human cancer cell lines, demonstrate that ERK5 inhibition activates cytotoxic autophagy, a process that triggers cancer cell death, without affecting healthy cells. A combination of ERK5 inhibitors and chemotherapy could improve cancer treatment.

The researchers published their findings in the journal Frontiers in Cell and Developmental Biology.

The synthesis of cellular proteins takes place at the endoplasmic reticulum. In response to different factors, such as lack of nutrients or of oxygen, endoplasmic reticulum become stressed, a process that can compromise the survival of cells. To deal with this, a process called UPR (Unfolded Protein Response) is started, to restore protein production and cellular normality. Among other strategies, UPR initiates autophagy, a biological process that allows cells to degrade and recycle defective components. However, if stress is extreme or prolonged, UPR is not enough to restore protein production, and UPR leads to a cytotoxic autophagy that activates apoptosis (cellular suicide). 

UPR occurs in all the body cells, but has special relevance in tumor cells, which present high levels of endoplasmic reticulum stress. UPR and autophagy allow tumor cells to better adapt to the environment and to avoid the immune system. Consequently, tumor cells are very sensitive to reach a level of autophagy that results toxic for the cell. Hence, autophagy modulation is a new therapeutic strategy to treat cancer: drugs that induce high levels of autophagy can cause the collapse of tumor cells, as well as the activation of the apoptotic cell death program.

ERK5 inhibitors sensitize tumor cells to chemotherapy, for which our research opens a very promising line for the improvement of chemotherapy as well as for more effective strategies to tackle cancer

José Miguel Lizcano

MAP kinase ERK5 protein controls the proliferation and survival of tumor cells, being a new therapeutic target for cancer treatment. ERK5 inhibitors have shown efficacy in different cell and tumor models, both as monotherapy and in combination with chemotherapy. However, the mechanism by which these inhibitors induce tumor cell death was unknown. 

A research team from the Vall d’Hebron Research and the Universitat Autònoma de Barcelona, led by José Miguel Lizcano -affiliated with both institutions-, has uncover the mechanism by which ERK5 inhibitors cause cancer cell death. Using human tumor cell cultures of pancreatic, endometrial and cervical cancer, researchers found that ERK5 regulates tumor autophagy. Thus, ERK5 inhibitors activate endoplasmic reticulum stress and UPR (which is already elevated in tumor cells) to levels that exceed their protective effect, activating a toxic form of autophagy that finally results in apoptotic death of tumor cells (a process called cytotoxic autophagy). "ERK5 inhibitors sensitize tumor cells to chemotherapy", explains José Miguel Lizcano, "for which our research opens a very promising line for the improvement of chemotherapy as well as for more effective strategies to tackle cancer". 


Source: Universitat Autònoma de Barcelona

23.12.2021

Read all latest stories

Related articles

Photo

News • Immune systems timulation

Using senescent cells as anti-cancer vaccines

Researchers from Barcelona report that vaccination with senescent cells shows promise in experimental models of melanoma and pancreatic cancer.

Photo

News • Filopodia research

'Sticky fingers' in cells keep breast cancer contained

Researchers in Finland have identified that finger-like cellular extensions called filopodia contribute to building a barrier surrounding breast tumours.

Photo

News • Desperate cancer cells

How tumors mutate their way out of a crisis (and become drug-resistant)

Researchers discovered that cancer cells mobilize a SOS response when they are desperate to resist anticancer drugs. The team also came up with an anti-SOS approach that blocked the mechanism in mice.

Related products

Fujifilm Wako – Autokit CH50 Assay

Immunoassays

Fujifilm Wako – Autokit CH50 Assay

FUJIFILM Wako Chemicals Europe GmbH
Mindray – BC-6200 / 6000 Auto Hematology Analyzer

Blood Cell Couner

Mindray – BC-6200 / 6000 Auto Hematology Analyzer

Shenzhen Mindray Bio-Medical Electronics Co., Ltd
Mindray – BC-6800Plus Auto Hematology Analyzer

Blood Cell Couner

Mindray – BC-6800Plus Auto Hematology Analyzer

Shenzhen Mindray Bio-Medical Electronics Co., Ltd
MolGen – PurePrep 96

Extraction

MolGen – PurePrep 96

MolGen
Subscribe to Newsletter